Surface Oncology Inc
Surface Oncology was created to advance next‐generation approaches to cancer immunotherapy based on proprietary insights about novel immunotherapy targets and emerging areas of cancer immuno‐biology. The company’s scientific founders and SAB are comprised of world‐leading immunologists and cancer researchers, including co‐chairs Sasha Rudensky (Memorial Sloan Kettering) and Arlene Sharpe (Harvard/DFCI). They are joined on the SAB by Christopher Hunter and John Wherry (University of Pennsylvania), Carla Rothlin (Yale University), Elliott Sigal, and John Stagg (University of Montreal).